



One involves



manufacturer owns at settlement or at any t

- o 6 of these final settlements involve resolution of an  review initiated by the generic manufacturer prior to its ANDA being filed, avoiding federal litigation entirely.

4 of these 6 settlements involve explicit compensation to the generic manufacturer in the form of litigation fees.

1 involves explicit compensation in the form of a side deal in which the brand manufacturer assigned the generic manufacturer five patents unrelated to the litigated product at no cost.

EXHIBIT 1

	FY2004	FY2005	FY2006	FY2007	FY2008	FY2009	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016	FY2017
Final Settlements	14	11	28	33	66	68	113	156	140	145	160	170	232	226
w/ Restriction on Generic Entry	2002 f 748.83		14	1392.4	16	19	0.631	28	402	29	21 re f 0.878		30	20 g